---
schema_version: "secwatch.filing_event.v1"
accession: "0001724521-24-000153"
form_type: "8-K"
ticker: "RCUS"
cik: "0001724521"
company_name: "Arcus Biosciences, Inc."
filed_at: "2024-10-24T23:59:59+00:00"
generated_at: "2026-05-30T10:34:08.716490+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Arcus reports casdatifan interim data: 34% ORR in heavily pre-treated ccRCC patients

## Summary
- ORR 34% (11/32) in efficacy-evaluable patients at 100 mg dose; confirmed ORR 25% (8/32).
- Disease control rate 81%; median progression-free survival not reached (data cutoff Aug 30, 2024).
- Patient population heavily pre-treated: 52% had ≥3 prior lines; 61% intermediate IMDC risk.
- Grade 3 TEAEs related to casdatifan were 42% (anemia 36%, hypoxia 9%); no deaths or life-threatening events.

## SEC filing metadata
- accession: 0001724521-24-000153
- form_type: 8-K
- ticker: RCUS
- cik: 0001724521
- company_name: Arcus Biosciences, Inc.
- filed_at: 2024-10-24T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 7.01, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1724521/000172452124000153/0001724521-24-000153-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1724521/000172452124000153/rcus-20241024.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001724521-24-000153
- JSON: https://secwatch.observer/filing/0001724521-24-000153.json
- Plain text: https://secwatch.observer/filing/0001724521-24-000153.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.